Orion Portfolio Solutions LLC purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 30,796 shares of the company's stock, valued at approximately $44,000. Orion Portfolio Solutions LLC owned 0.08% of BeyondSpring as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. Decheng Capital Management III Cayman LLC acquired a new position in BeyondSpring in the first quarter valued at approximately $10,908,000. BlackRock Inc. raised its position in shares of BeyondSpring by 20.8% during the first quarter. BlackRock Inc. now owns 1,861,219 shares of the company's stock worth $4,095,000 after purchasing an additional 320,428 shares during the period. State Street Corp raised its position in shares of BeyondSpring by 11.5% during the first quarter. State Street Corp now owns 563,670 shares of the company's stock worth $1,240,000 after purchasing an additional 57,933 shares during the period. Renaissance Technologies LLC raised its position in shares of BeyondSpring by 831.9% during the first quarter. Renaissance Technologies LLC now owns 282,373 shares of the company's stock worth $621,000 after purchasing an additional 252,073 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of BeyondSpring by 19.6% during the first quarter. BNP Paribas Arbitrage SA now owns 131,477 shares of the company's stock worth $289,000 after purchasing an additional 21,587 shares during the period. 23.35% of the stock is owned by institutional investors and hedge funds.

BeyondSpring Stock Down 4.4 %

Shares of NASDAQ:BYSI opened at $0.97 on Wednesday. BeyondSpring Inc. has a twelve month low of $0.94 and a twelve month high of $17.98. The stock's 50 day moving average is $1.40 and its 200-day moving average is $1.62. The firm has a market capitalization of $37.95 million, a price-to-earnings ratio of -0.59 and a beta of 1.03.

About BeyondSpring

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

Featured Stories

• Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
• Defensive Stocks For A Volatile Market
• SunPower Is Ready To Power Up Triple-Digit Earnings Gains
• Will UPS Be Next to Deliver a Warning?
• Is This the Darkest Before the Dawn for Gap Stock?
• Build A Better Tech Portfolio With Jabil Inc.

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.